Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2019-02-05 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Invitation to fourth quarter and preliminary 2018 result presentation
Report Publication Announcement Classification · 98% confidence The document is a short announcement (3297 characters) dated February 5, 2019, stating that PCI Biotech invites stakeholders to a presentation of the company's 'fourth quarter and preliminary 2018 report' scheduled for February 13, 2019. It specifies the time, venue, and notes that the interim report and presentation will be available on newsweb.no and the company's webpage at 07:30 am on the day of the event. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication or availability of a report, rather than containing the full report content, should be classified as a Report Publication Announcement (RPA).
2019-02-05 English
PCI Biotech: Invitation to fourth quarter and preliminary 2018 result presentation
Report Publication Announcement Classification · 95% confidence The document is titled "PCI Biotech: Invitation to fourth quarter and preliminary 2018 result presentation" and explicitly invites recipients to a presentation of the Q4 and preliminary 2018 results scheduled for February 13, 2019. It states that the interim report and the presentation will be available on newsweb.no and the company's webpage at 07:30am CET on that date. Since the document's primary function is to announce the upcoming release and presentation of financial results (which are for a period shorter than a year, i.e., Q4/preliminary 2018), it functions as an announcement of an earnings event. However, the core content is the invitation and details about the presentation itself, not the full financial report (IR) or the initial highlights (ER). Given the specific nature of announcing the *presentation* of results, and considering the short length (2882 chars) which suggests it's not the full report, this fits best as an announcement regarding the publication of reports. The closest fit among the options is 'Report Publication Announcement' (RPA), as it announces when and where the report/presentation will be available, or 'Call Transcript' (CT) if it were the transcript, but it is an invitation. Since it announces the release of the report/presentation, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule, as it is an announcement *about* the report/presentation, not the report itself.
2019-02-05 English
PCI Biotech: Preliminary confirmation of safety read-out from the fimaChem Phase I extension study in bile duct cancer
Earnings Release Classification · 99% confidence The document is a press release dated December 20, 2018, announcing preliminary confirmation that the safety endpoint has been reached in a Phase I extension study for their drug fima*Chem*. It discusses clinical trial progress, upcoming pivotal study design, endpoints (PFS, OS), and regulatory interactions (EMA, FDA). This type of announcement, detailing clinical trial updates and operational milestones, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive update on clinical progress rather than a comprehensive financial report (10-K, IR) or a general regulatory notice, it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it's a mandatory disclosure not covered elsewhere. Given the focus on clinical trial results and future study plans, it functions as a key operational update often bundled with earnings or released separately as a material event. Since it is not a full financial report, and it is a specific material event announcement, RNS is the most appropriate general regulatory fallback, although ER is plausible if this was released around an earnings period. However, based on the content being a specific clinical trial update, RNS (Regulatory Filings/General Announcement) is the safest classification for material, non-standard report announcements. Q4 2018
2018-12-20 English
PCI Biotech: Preliminary confirmation of safety read-out from the fimaChem Phase I extension study in bile duct cancer
Regulatory Filings Classification · 95% confidence The document is a press release from PCI Biotech announcing preliminary safety results from a Phase I extension study for their fimaChem treatment in bile duct cancer. It discusses clinical trial progress, regulatory interactions (EMA, FDA), and future study plans (pivotal study). This type of announcement, detailing clinical trial updates and operational progress outside of formal quarterly financial reporting (10-K, IR) or specific shareholder actions (DIV, DVA), most closely aligns with a general regulatory announcement or news release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a specific update on clinical development, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for non-standard, material company news releases, especially those subject to disclosure requirements like the Norwegian Securities Trading Act mentioned at the end.
2018-12-20 English
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company
M&A Activity Classification · 99% confidence The document is a short press release dated December 18, 2018, announcing the extension of a preclinical research collaboration between PCI Biotech and an undisclosed top-10 pharma company. It details the extension period (6 months) and the purpose (evaluating synergistic effects of technology platforms). This type of announcement, which details ongoing business development, partnerships, or research progress outside of standard financial reporting periods (like earnings or annual reports), typically falls under general corporate news. Since it is not a formal financial report (10-K, IR, ER), a management change (MANG), a director's trade (DIRS), or a specific financing event (CAP), the most appropriate classification is the general regulatory announcement/news category, RNS, as it is a material update disclosed to the market.
2018-12-18 English
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company
Regulatory Filings Classification · 95% confidence The document is a short press release dated December 18, 2018, announcing the extension of a preclinical research collaboration agreement between PCI Biotech and an undisclosed top-10 pharma company. It details the extension period (6 months) and the purpose (evaluating synergistic effects of technology platforms). This type of announcement, which details ongoing business development, partnership updates, or research progress outside of standard financial reporting periods (like earnings or annual reports), typically falls under general corporate news or regulatory filings. Since it is not a formal financial report (10-K, IR, ER), a management change (MANG), a dividend notice (DIV), or a specific transaction (POS, TAR), it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the collaboration involved significant financial terms, but the focus here is on the research agreement itself. Given the nature of the announcement—a specific business development update that is likely required for disclosure—RNS is the most appropriate general category for non-standard corporate news.
2018-12-18 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.